C5-targetting monoclonal antibody clears Phase I trials

Monoclonal antibody

Biotechnology company ImmunAbs has announced the successful completion of a Phase I clinical trial for IM-101, a humanised monoclonal antibody targeting complement C5.

The complement system is widely acknowledged for its critical involvement in autoimmune diseases.

The randomised, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and preliminary efficacy of IM-101.

Healthy volunteers were enrolled to receive a single-ascending dose of IM-101 or placebo. Notably, IM-101 demonstrated good tolerability, with no severe adverse events or dose limiting toxicity (DLT) observed at any tested dosage. The trial successfully met all predefined endpoints.

Dr Dongjo Kim, CEO of ImmunAbs, said: “We are excited to share that the topline results are positive. In this trial, we assessed a critical biomarker for complement inhibition – serum free C5 concentration – confirming the efficacy of IM-101 in binding to C5 in humans. These outcomes lay a solid foundation for addressing the unmet medical needs of patients experiencing residual symptoms despite receiving the current standard of care. We eagerly await to see the therapeutic potential of IM-101 in the forthcoming Phase II study.”

ImmunAbs is actively pursuing additional investment and collaboration with the healthcare community to advance IM-101 towards market release.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free